^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KY1043
i
Other names: KY1043, KY 1043
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sanofi
Drug class:
PD-L1 inhibitor, IL-2 stimulant
Related drugs:
almost4years
[VIRTUAL] KY1043, a novel CD25-directed PD-L1 IL-2 immunocytokine, delivers potent anti-tumor activity in vivo via an expansion of a Tcf1hi PD-1+ CD8+ T cell population (AACR-II 2020)
In conclusion, KY1043 induces highly effective tumor killing in vivo, believed to be driven by the preferential expansion of a recently discovered ‘stem-like’ CD8+ T cell population in the tumor microenvironment. These results challenge the dogma that selective binding to the dimeric ‘βγ’ IL-2R is required for tumor control and demonstrate that a CD25-directed immunocytokine may provide an advantageous therapeutic-index for the treatment of cancer.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • FOXP3 (Forkhead Box P3)
|
PD-1 expression
|
KY1043
Share via
